

PRODUCT MONOGRAPH

^{Pr}MINT-FUROSEMIDE

furosemide

20 mg, 40 mg and 80 mg Tablets

USP

Diuretic

Mint Pharmaceuticals Inc.
1093 Meyerside Drive, Unit 1
Mississauga, Ontario
L5T 1J6

Date of Preparation:
July 21, 2017

Submission Control No: **166281**

Table of Contents

PART I: HEALTH PROFESSIONAL INFORMATION.....	3
SUMMARY PRODUCT INFORMATION.....	3
INDICATIONS AND CLINICAL USE	3
CONTRAINDICATIONS	4
WARNINGS AND PRECAUTIONS	5
ADVERSE REACTIONS.....	9
DRUG INTERACTIONS	11
DOSAGE AND ADMINISTRATION	15
OVERDOSAGE	15
ACTION AND CLINICAL PHARMACOLOGY	16
STORAGE AND STABILITY.....	18
DOSAGE FORMS, COMPOSITION AND PACKAGING	18
PART II: SCIENTIFIC INFORMATION	19
PHARMACEUTICAL INFORMATION	19
CLINICAL TRIALS	20
DETAILED PHARMACOLOGY	20
TOXICOLOGY	21
REFERENCES	23
PART III: CONSUMER INFORMATION.....	25

Pr MINT-FUROSEMIDE
furosemide
20 mg, 40 mg and 80 mg Tablets
USP

PART I: HEALTH PROFESSIONAL INFORMATION

SUMMARY PRODUCT INFORMATION

Route of Administration	Dosage Form / Strength	Nonmedicinal Ingredients
Oral	Tablet	
	20 mg	20 mg: corn starch, lactose monohydrate, magnesium stearate, pregelatinized starch and sodium starch glycolate.
	40 mg	40 mg: Color D&C Yellow No. 10, corn starch, FD&C Yellow No. 6 Aluminum Lake, lactose monohydrate, magnesium stearate, pregelatinized starch and sodium starch glycolate.
	80 mg	80 mg: Color D&C Yellow No. 10, corn starch, FD&C Yellow No. 6 Aluminum Lake, lactose monohydrate, magnesium stearate, pregelatinized starch and sodium starch glycolate.

INDICATIONS AND CLINICAL USE

MINT-FUROSEMIDE (furosemide) is indicated for:

- The treatment of edema associated with congestive heart failure, cirrhosis of the liver and renal disease including, nephrotic syndrome, as well as other edematous states amenable to diuretic therapy.
- Can also be used alone, in the control of mild to moderate hypertension, or in combination with other antihypertensive agents in more severe cases.

Hypertensive patients who cannot be adequately controlled with thiazides will probably also not be adequately controllable with furosemide alone.

Pediatrics

When administered to children, MINT-FUROSEMIDE therapy should be instituted in the hospital, in carefully selected patients, under close observation with frequent monitoring of serum

electrolytes (see DOSAGE AND ADMINISTRATION section).

The available pediatric data does not allow for a recommendation of a specific age range in this population.

Geriatrics (> 61 years of age)

Use in the geriatric population is associated with differences in safety (see WARNINGS AND PRECAUTIONS).

CONTRAINDICATIONS

MINT-FUROSEMIDE (furosemide) is contraindicated in:

- Patients who are hypersensitive to furosemide, sulfonamide-derived drugs or to any ingredient in the formulation or component of the container. For a complete listing, see the Dosage Forms, Composition and Packaging section of the product monograph. Patients allergic to sulfonamides (e.g. sulfonamide antibiotics or sulfonyleureas) may show cross-sensitivity to furosemide.
- Patients with complete renal shutdown. If increasing azotemia and oliguria occur during treatment of severe progressive renal disease, the drug should be discontinued.
- Patients with hepatic coma and precoma or in states of electrolyte depletion until the basic condition is improved or corrected. Therapy with MINT-FUROSEMIDE should not be initiated in these patients (see WARNINGS AND PRECAUTIONS, Hepatic/Biliary/Pancreatic section).
- Severe hyponatremia, hypokalemia, hypovolemia, dehydration or hypotension must be regarded as contraindications until serum electrolytes and fluid balance and blood pressure have been restored to normal levels (see WARNINGS AND PRECAUTIONS and ADVERSE REACTIONS sections).
- As furosemide may be capable of displacing bilirubin from albumin at least "*in vitro*", it should not be administered to jaundiced newborn infants or to infants suffering from diseases (e.g. Rh incompatibility, familial non-hemolytic jaundice, etc.) with the potential of causing hyperbilirubinemia and possibly kernicterus.
- Women must not breast-feed if they are treated with furosemide (see WARNINGS AND PRECAUTIONS section).

WARNINGS AND PRECAUTIONS

General

MINT-FUROSEMIDE (FUROSEMIDE) IS A POTENT DIURETIC WHICH IF GIVEN IN EXCESSIVE AMOUNTS CAN LEAD TO A PROFOUND DIURESIS WITH WATER AND ELECTROLYTE DEPLETION. THEREFORE, CAREFUL MEDICAL SUPERVISION IS REQUIRED, AND DOSE AND DOSE SCHEDULE HAVE TO BE ADJUSTED TO THE INDIVIDUAL PATIENT'S NEEDS (SEE DOSAGE AND ADMINISTRATION).

All patients receiving MINT-FUROSEMIDE therapy should be observed for signs and symptoms of fluid or electrolyte imbalance, hyponatremia, hypochloremic alkalosis, hypovolemia, hypomagnesemia, or hypocalcemia: dryness of the mouth, thirst, weakness, lethargy, drowsiness, restlessness, muscle pain or cramps, muscular fatigue, hypotension, oligourea, tachycardia, arrhythmia, or gastro-intestinal disturbances such as nausea and vomiting, increases in blood glucose and alteration in glucose tolerance tests.

During long-term therapy a high-potassium diet is recommended. Potassium supplements may be required especially when high doses are used for prolonged periods. Some electrolyte disturbances (e.g. hypokalemia, hypomagnesemia) may increase the toxicity of certain other drugs (e.g. digitalis preparations and drugs inducing QT interval prolongation syndrome). Particular caution with potassium levels is necessary when the patient is on digitalis glycosides, potassium-depleting steroids, or in the case of infants and children. Potassium supplementation, diminution in dose, or discontinuation of MINT-FUROSEMIDE therapy may be required.

Since rigid sodium restriction is conducive to both hyponatremia and hypokalemia, strict restriction in sodium intake is not advisable in patients receiving MINT-FUROSEMIDE therapy.

Urinary outflow must be secured. Patients with urinary outflow require careful monitoring- especially during the initial stages of treatment (see ADVERSE REACTIONS-Post-Market Adverse Drug Reactions-Renal and urinary disorders section).

Concomitant use with risperidone

In risperidone placebo-controlled trials in elderly patients with dementia, a higher incidence of mortality was observed in patients treated with furosemide plus risperidone (7.3%; mean age 89 years, range 75-97 years) when compared to patients treated with risperidone alone (3.1%; mean age 84 years, range 70-96 years) or furosemide alone (4.1%; mean age 80 years, range 67-90 years). Concomitant use of risperidone with other diuretics (mainly thiazide diuretics used in low dose) was not associated with similar findings.

No pathophysiological mechanism has been identified to explain this finding, and no consistent pattern for cause of death observed. Nevertheless, caution should be exercised and the risks and benefits of this combination or co-treatment with other potent diuretics should be considered prior to the decision to use. There was no increased incidence of mortality among patients taking other

diuretics as concomitant treatment with risperidone. Irrespective of treatment, dehydration was an overall risk factor for mortality (see CONTRAINDICATIONS section) and should therefore be avoided in elderly patients with dementia.

Carcinogenesis and Mutagenesis

Carcinogenicity: Furosemide in the approximate amount of 200 mg/kg body weight daily was administered to female mice and rats over a 2-year period with their diet. An increased incidence of mammary adenocarcinoma was noted in the mice, but not in the rats. These tumors occurred with a positive trend, and the incidence in the high dose group was increased compared to the control, in addition, the high-dose rate was about five fold over the historical rate. These tumors are considered to be associated with furosemide administration. This dose is considerably greater than the therapeutic dose administered in human patients.

In a carcinogenicity study, rats were administered furosemide in daily doses of 15 and 30 mg/kg body weight. Male rats in the 15 mg/kg-dose category, but not in the 30 mg/kg-dose category, showed a marginal increase in uncommon tumours.

Mutagenicity: In in-vitro tests on bacteria and mammalian cells, both positive and negative results have been obtained. Induction of gene and chromosome mutations, however, has been observed only where furosemide reached cytotoxic concentrations.

Ear/Nose/Throat

Cases of tinnitus and reversible deafness have been reported. There have also been some reports of cases, the majority in children undergoing renal transplantation, in which permanent deafness has occurred. In these latter cases, the onset of deafness was usually insidious and gradually progressive up to 6 months after furosemide therapy. Hearing impairment is more likely to occur in patients with hypoproteinaemia or severely reduced renal function or in patients who are also receiving drugs known to be ototoxic. Since this may lead to irreversible damage, these drugs must only be used with furosemide if there are compelling medical reasons.

Endocrine and Metabolism

Increases in blood glucose and alterations in glucose tolerance tests with abnormalities of the fasting and two-hour postprandial blood sugar levels have been observed. Rare cases of precipitation of diabetes mellitus have been reported.

Asymptomatic hyperuricemia can occur and a gout attack may rarely be precipitated.

Hepatic/Biliary/Pancreatic

It may be advisable to hospitalize patients with hepatic cirrhosis and ascites prior to initiating therapy. Sudden alterations of fluid and electrolyte balance in patients with cirrhosis may precipitate hepatic coma, therefore, strict observation is necessary during the period of diuresis. Supplemental potassium chloride and, if required, an aldosterone antagonist, are helpful in preventing hypokalemia and metabolic alkalosis (see CONTRAINDICATIONS section).

Particularly careful monitoring is necessary in patients with hepatorenal syndrome.

Peri-Operative Considerations

Sulfonamide diuretics have been reported to decrease arterial responsiveness to pressor amines and to enhance the effect of tubocurarine. Great caution should be exercised in administering curare or its derivatives to patients undergoing therapy with MINT-FUROSEMIDE and it is advisable to discontinue MINT-FUROSEMIDE for one week prior to any elective surgery.

Special Populations

Pregnant Women

The teratogenic and embryotoxic potential of furosemide in humans is unknown. The drug should not be used in pregnant women or in women of childbearing potential unless in the opinion of the attending physician the benefits to the patient outweigh the possible risk to the foetus.

Reproductive and teratological studies have been performed in mice, rats, rabbits, cats, dogs and monkeys. With the exception of mice and rabbits, no abnormalities attributed to furosemide were detected. Furosemide caused unexplained maternal deaths and abortions in the rabbit at a daily dose of 50 mg/kg (approximately three times the maximum recommended human daily dose of 1000 mg orally) when administered between days 12 to 17 of gestation. In another study in rabbits, a dose of 25 mg/kg caused maternal deaths and abortions. In a third study, none of the pregnant rabbits survived a dose of 100 mg/kg. Data from the above studies indicate foetal lethality which can precede maternal deaths.

The results of a mouse study and one of the three rabbit studies also showed an increased incidence of distention of the renal pelvis and, in some cases, of the ureters in foetuses derived from treated dams as compared to the incidence of foetuses from the control group.

Treatment during pregnancy requires monitoring of fetal growth.

Nursing Women

It should be noted that diuretics may partially inhibit lactation and that furosemide passes into the breast milk. Women must not breast-feed if they are treated with furosemide (see CONTRAINDICATIONS section).

Pediatrics

Furosemide may lower serum calcium levels, and rare cases of tetany have been reported. Accordingly, periodic serum calcium levels should be obtained.

In premature infants furosemide may precipitate nephrocalcinosis/nephrolithiasis. When administered to premature infants with respiratory distress syndrome in the first few weeks of life, diuretic treatment with furosemide may accentuate the risk of a patent ductus arteriosus (see WARNINGS AND PRECAUTIONS- Monitoring and Laboratory Tests section).

Caution is required in neonates because of prolonged half-life of furosemide.

Geriatrics (> 61 years of age)

Excessive diuresis induced by furosemide may result in dehydration and reduction of blood volume, with circulatory collapse and with the possibility of vascular thrombosis and embolism particularly in elderly patients. Furosemide may cause electrolyte depletion.

Furosemide binding to albumin may be reduced in elderly patients.

The drug is known to be substantially excreted unchanged by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal functions, care should be taken in dose selection and may be useful to monitor renal function.

In general dose selection for the elderly patients should be cautious, usually starting at the low end of dosage range, reflecting the greater frequency of decreased hepatic, renal or cardiac function, and the concomitant disease or other drug therapy.

Monitoring and Laboratory Tests

Frequent serum electrolyte, creatinine and CO₂ content determinations should be performed during the first few months of therapy and periodically thereafter. It is essential to replace electrolyte losses and to maintain fluid balance so as to avoid any risk of electrolyte depletion (hyponatremia, hypochloremia, hypokalemia, hypomagnesemia or hypocalcemia), hypovolemia, or hypotension.

Checks on urine and blood glucose should be made at regular intervals especially in diabetics and in those suspected of latent diabetes when receiving MINT-FUROSEMIDE. Increases in blood glucose and alterations in glucose tolerance tests with abnormalities of the fasting and two-hour postprandial blood sugar levels have been observed.

Frequent BUN determinations during the first few months of therapy and periodically thereafter, as well as regular observations for possible occurrence of blood dyscrasias, liver damage or idiosyncratic reactions are advisable.

Particularly careful monitoring is necessary in:

- patients with hypoproteinaemia. Cautious dose titration is required.
- premature infants. Renal function must be monitored and renal ultrasonography performed.
- patients with hypotension
- patients who would be at particular risk from a pronounced fall in blood pressure (e.g. patients with significant stenoses of the coronary arteries or of the blood vessels supplying the brain).
- patients with hepatorenal syndrome.
- patients with latent and manifest diabetes mellitus
- patients with gout

Occupational Hazards

Furosemide may lower the state of patient alertness and/or reactivity particularly at the start of treatment as a result of a reduction in blood pressure and of other adverse reactions

(see ADVERSE REACTIONS section).

ADVERSE REACTIONS

Clinical Trial Adverse Drug Reactions

No data available.

Post-Market Adverse Drug Reactions

Adverse reactions are categorized below by body system.

Blood and lymphatic system disorders

Anemia, eosinophilia, leukopenia and thrombocytopenia (with purpura) have occurred, as well as agranulocytosis, aplastic anemia and hemolytic anemia.

Ear and Labyrinth disorders

Cases of tinnitus and sometimes irreversible deafness have been reported. There have also been some reports of cases, the majority in children undergoing renal transplantation, in which permanent deafness has occurred. In these latter cases, the onset of deafness is usually insidious and gradually progressive up to 6 months after furosemide therapy. Hearing disorder is more likely to occur in patients with hypoproteinaemia or severely reduced renal function who are also receiving drugs known to be ototoxic.

Vertigo has been reported.

Eye disorders

Xanthopsia and blurred vision have been reported.

Gastrointestinal disorders

Acute pancreatitis, oral and gastric burning, diarrhea, nausea, vomiting and constipation have been reported. Rare occurrence of sweet taste has been reported.

Hepatobiliary disorders

Jaundice (intrahepatic cholestatic jaundice) and cholestasis have been reported

Immune system disorders

Hypersensitivity reactions to furosemide also include photosensitivity, paresthesia and fever. Systemic hypersensitivity reactions include vasculitis and necrotizing angiitis.

Severe anaphylactic or anaphylactoid reactions (e.g. with shock) occur rarely.

Investigations

Increase in liver transaminases has been reported.

Transient elevations of BUN have been observed, especially in patients with renal insufficiency.

As with other diuretics, there may be an increase in serum creatinine, uric acid (this may lead to

gout attack in predisposed patients), blood urea, cholesterol and triglyceride levels during furosemide treatment.

Metabolism and nutrition disorders

Electrolyte depletion has occurred during therapy with furosemide, especially in patients receiving higher doses with a restricted salt intake. Electrolyte depletion (hyponatremia, hypochloremia, hypokalaemia, hypocalcemia and hypomagnesemia) manifests itself by adverse reactions attributed to various body systems: weakness, dizziness, drowsiness, polyuria, polydipsia, orthostatic hypotension, lethargy, sweating, bladder spasms, anorexia, vomiting, mental confusion, meteorism, thirst, headache, muscle cramp, muscle weakness, tetany and disorder of cardiac rhythm (see WARNINGS AND PRECAUTIONS section).

The development of electrolyte disturbances (including symptomatic) is influenced by factors such as underlying diseases (e.g. liver cirrhosis, cardiac failure), concomitant medication and nutrition.

Cases of Pseudo-Bartter syndrome ((hypochloremia, hypokalaemia, alkalosis, normal to low blood pressures, and elevated plasma renin and aldosterone) have been reported in the context of misuse and/or long-term use of furosemide.

Treatment with furosemide has occasionally caused some deterioration of metabolic control in cases of manifest diabetes, or has made latent diabetes manifest.

Metabolic alkalosis may develop in the form of a gradually increasing electrolyte deficit or, e.g. where higher furosemide doses are administered to patients with normal renal function, acute severe electrolyte losses.

Pre-existing metabolic alkalosis (e.g. in decompensated cirrhosis of the liver) may be aggravated.

In extreme cases, hypovolemia may lead to dehydration, circulatory collapse, hemoconcentration and thrombophilia. Thrombophlebitis and emboli have been reported.

Nervous system disorders

At the commencement of treatment, excessive diuresis may give rise, especially in elderly patients, to a feeling of pressure in the head, dizziness.

Paresthesia has been reported.

Hepatic encephalopathy in patients with hepatocellular insufficiency has been reported.

Renal and urinary disorders

Symptoms of obstructed micturition (e.g. in hydronephrosis, prostatic hypertrophy, ureterostenosis) may become manifest or may be aggravated during medication with diuretics.

Interstitial nephritis has been reported.

Increased production of urine may provoke or aggravate complaints in patients with an obstruction of urinary outflow. Thus, acute retention of urine with possible secondary complications may occur. Increases in urine sodium and chloride have also been reported.

There have been some reported cases of renal failure.
In premature infants furosemide may precipitate nephrocalcinosis/nephrolithiasis.

Skin and subcutaneous tissue disorders

Various forms of dermatitis (e.g. dermatitis bullous), including urticaria, erythema multiforme, pemphigoid, Stevens-Johnson syndrome, toxic epidermal necrolysis, exfoliative dermatitis, pruritus, epidermolysis bullosa, AGEP (acute generalized exanthematous pustolosis) and DRESS (Drug Rash with Eosinophilia and Systemic Symptoms) have occurred.

Dermatologic reactions to furosemide also include purpura and rash.

Vascular disorders

Too vigorous diuresis may induce orthostatic hypotension or acute hypotensive episodes, which may cause signs and symptoms such as impairment of concentration and reactions, lightheadedness or orthostatic intolerance. There have been some reported cases of thrombosis.

When administered to premature infants with respiratory distress syndrome in the first few weeks of life, diuretic treatment with furosemide may accentuate the risk of a patent ductus arteriosus.

DRUG INTERACTIONS

Overview

Sulfonamide diuretics have been reported to decrease arterial responsiveness to pressor amines and to enhance the effect of tubocurarine or curare-type muscle relaxants (see WARNINGS AND PRECAUTIONS – Peri-Operative Considerations section).

In case of concomitant abuse of laxatives, the risk of an increased potassium loss should be considered.

Glucocorticoids, carbenoxolone and licorice may also increase potassium loss.

Administration of MINT-FUROSEMIDE to diabetic patients may result in possible decrease of diabetic control. Dosage adjustments of the anti-diabetic agent may be needed.

Hearing impairment is more likely to occur in patients who are also receiving drugs known to be ototoxic (e.g. aminoglycosides antibiotics, ethacrynic acid and cisplatin) (see WARNINGS AND PRECAUTIONS section).

In edematous hypertensive patients being treated with antihypertensive agents, care should be taken to reduce the dose of these drugs when MINT-FUROSEMIDE is administered, since furosemide potentiates their hypotensive effect.

Non-steroidal anti-inflammatory drugs (e.g. indomethacin, acetyl-salicylic acid) may attenuate the effect of furosemide and may cause renal failure in case of pre-existing hypovolemia.

Drug-Drug Interactions

The drug interactions discussed in this section are based on either drug interaction case reports, or studies, or potential interactions due to the expected magnitude and seriousness of the interaction (i.e., those identified as contraindicated).

Established or Predicted Drug-Drug Interactions

Proper Name	Ref	Effect	Clinical Comments
Anticonvulsants			
Carbamazepine Phenobarbital Phenytoin	T	↓ furosemide diuretic effect	Anticonvulsant drugs (phenytoin, carbamazepine, phenobarbital), which, like furosemide, undergo significant renal tubular secretion, may also attenuate the effect of furosemide.
Antidiabetics			
Antidiabetics	T	↓ antidiabetic drug effect	The effects of antidiabetic drugs may be reduced.
Antihypertensive Agents			
ACE inhibitors	CT	↓ blood pressure and renal function	Especially in combination with ACE inhibitors, a marked hypotension may be seen sometimes progressing to shock. The concomitant administration of MINT-FUROSEMIDE with ACE-inhibitors may lead to deterioration in renal function and, in isolated cases, to acute renal failure. Consideration must be given to interrupting the administration of furosemide temporarily or at least reducing the dose of furosemide for three days before starting treatment with, or increasing the dose of, an
Angiotensin II receptor antagonists	CT	↓ blood pressure and renal function	Especially in combination with angiotensin II receptor antagonists, a marked hypotension may be seen sometimes progressing to shock. The concomitant administration of MINT-FUROSEMIDE with angiotensin II receptor antagonists may lead to deterioration in renal function and, in isolated cases, to acute renal failure. Consideration must be given to interrupting the administration of furosemide temporarily or at least reducing the dose of furosemide for three days before starting treatment with, or increasing the dose of, an angiotensin II receptor
Cephalosporins			
Cephalosporins	T	↓ renal function	Impairment of renal function may develop in patients receiving concurrent treatment with furosemide and high doses of certain cephalosporins.
Chloral Hydrate			
Chloral Hydrate	C	—	In isolated cases intravenous administration of furosemide within 24 hours of taking chloral hydrate may lead to flushing, sweating attacks, restlessness, nausea, increase in blood pressure and tachycardia. Use of furosemide concomitantly with chloral hydrate is therefore not recommended.

Proper Name	Ref	Effect	Clinical Comments
Chlorothiazides			
Chlorothiazides	T	—	The concurrent use of furosemide with chlorothiazide has been reported to decrease hypercalciuria and to dissolve some calculi.
Cisplatin			
Cisplatin	T	↑ nephrotoxicity ↑ ototoxicity	Nephrotoxicity of cisplatin may be enhanced if furosemide is not given in low doses and with positive fluid balance when used to achieve forced diuresis during cisplatin treatment. There is also a risk of ototoxic effects if cisplatin and furosemide are given concomitantly.
Cyclosporine			
Cyclosporine	CT	—	Concomitant use of cyclosporine A and furosemide is associated with increased risk of gouty arthritis secondary to furosemide-induced hyperurecemia and cyclosporine impairment of renal urate excretion.
Digitalis Glycosides			
Digitalis Glycosides	T	↓ potassium plasma concentration	Some electrolyte disturbances (e.g. hypokalemia, hypomagnesemia) may increase the toxicity of certain other drugs (e.g. digitalis preparations and drugs inducing QT interval prolongation syndrome). Particular caution with potassium levels is necessary when the patient is on digitalis glycosides. Potassium supplementation, diminution in dose, or discontinuation of MINT-FUROSEMIDE therapy may be required (see WARNINGS AND PRECAUTIONS).
Lithium			
Lithium	T	↑ lithium plasma concentration	Renal clearance of lithium is decreased in patients receiving MINT-FUROSEMIDE, resulting in increased risk of cardiotoxic and neurotoxic effects of lithium. Therefore, it is recommended that lithium levels be carefully monitored in patients receiving this
Methotrexate			
Methotrexate	T	↓ furosemide diuretic effect	Methotrexate, which like furosemide, undergoes significant renal tubular secretion, may also attenuate the effect of furosemide.
Nephrotoxic Drugs			
Nephrotoxic Drugs	T	↑ nephrotoxicity	The harmful effects of nephrotoxic drugs on the kidney may be increased.
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)			
Indomethacin	CT	↓ furosemide diuretic effect	Clinical studies have shown that the administration of indomethacin can reduce the natriuretic and anti-hypertensive effect of furosemide in some patients. This response has been attributed to inhibition of prostaglandin synthesis by indomethacin. Therefore, when indomethacin is added to the treatment of a patient receiving MINT-FUROSEMIDE, or MINT-FUROSEMIDE is added to the treatment of a patient receiving indomethacin, the patient should be closely observed to determine if the desired effect of furosemide is obtained. Indomethacin blocks the furosemide -induced increase in plasma-renin activity. This fact should be kept in mind when

Proper Name	Ref	Effect	Clinical Comments
			activity in hypertensive patients.
Potassium-depleting Steroids			
Potassium-depleting Steroids	T	↓ potassium plasma concentration	Some electrolyte disturbances (e.g. hypokalemia, hypomagnesemia) may increase the toxicity of certain other drugs (e.g. digitalis preparations and drugs inducing QT interval prolongation syndrome). Particular caution with potassium levels is necessary when the patient is on potassium-depleting steroids. Potassium supplementation, diminution in dose, or discontinuation of MINT-FUROSEMIDE therapy may be required (see WARNINGS AND PRECAUTIONS).
Probenecid			
Probenecid	T	↓ furosemide diuretic effect	Probenecid, which like furosemide, undergoes significant renal tubular secretion, may also attenuate the effect of furosemide.
Radiocontrast Agents			
Radiocontrast Agents	CT	↑ radiocontrast nephropathy	Patients who were at high risk for radiocontrast nephropathy treated with furosemide experienced a higher incidence of deterioration in renal function after receiving radiocontrast compared to high-risk patients who received only intravenous hydration prior to receiving radiocontrast.
Risperidone			
Risperidone	CT	—	Caution should be exercised and the risks and benefits of the combination or co-treatment with furosemide or with other potent diuretics should be considered prior to the decision to use. See PRECAUTIONS section, regarding increased mortality in elderly patients with dementia concomitantly receiving risperidone.
Salicylates			
Salicylates	T	↑ salicylate toxicity	Patients receiving high doses of salicylates in conjunction with MINT-FUROSEMIDE may experience salicylate toxicity at lower doses because of competition for renal
Sucralfate			
Sucralfate	T	↓ furosemide absorption	Concurrent administration of MINT-FUROSEMIDE and sucralfate should be avoided, as sucralfate reduces the absorption of furosemide from the intestine and hence weakens its effect.
Theophylline			
Theophylline	T	↑ theophylline effect	The effects of theophylline may be increased.

Legend: C= Case Study; CT= Clinical Trial; T= Theoretical

Interactions with other drugs have not been established.

Drug-Food Interactions

Interactions with food have not been established.

Drug-Herb Interactions

Interactions with herbal product have not been established.

Drug-Laboratory Interactions

Interactions with laboratory tests have not been established.

DOSAGE AND ADMINISTRATION

Dosing Considerations

Careful observations for changes in blood pressure must be made when MINT-FUROSEMIDE is used with other antihypertensive drugs, especially during initial therapy. The dosage of other agents must be reduced by at least 50% as soon as MINT-FUROSEMIDE is added to the regimen to prevent excessive drop in blood pressure. As the blood pressure falls under the potentiating effect of furosemide, a further reduction in dosage or even discontinuation of other antihypertensive drugs may be necessary.

Recommended Dose and Dosage Adjustment

Adults (oral)

Edema

The usual initial dose of MINT-FUROSEMIDE is 40 to 80 mg. Ordinarily a prompt diuresis ensues and the starting dose can then be maintained or even reduced. If a satisfactory diuresis has not occurred within 6 hours, succeeding doses should be increased by increments of 20 to 40 mg, if necessary. Maximum daily dose: 200 mg. Once the effective single dose has been determined, it may be repeated 1 to 3 times a day.

The mobilization of edema may be most efficiently and safely accomplished by utilizing an intermittent dosage schedule in which MINT-FUROSEMIDE is given for 2 to 4 consecutive days each week. With doses exceeding 120 mg/day, careful clinical and laboratory observations are particularly advisable.

Hypertension

A dosage schedule of 20 to 40 mg twice daily is recommended. Individualized therapy is of great importance. It is further recommended, if 40 mg twice daily does not lead to a clinically satisfactory response, to add other antihypertensive agents, rather than to increase the dose of MINT-FUROSEMIDE.

OVERDOSAGE

Symptoms

Dehydration, electrolyte depletion and hypotension may be caused by overdosage or accidental ingestion. In cirrhotic patients, overdosage might precipitate hepatic coma.

The clinical picture in acute or chronic overdose depends primarily on the extent and consequences of electrolyte and fluid loss, e.g. hypovolemia, dehydration, hemoconcentration, cardiac arrhythmias (including A-V block and ventricular fibrillation). Symptoms of these

disturbances include severe hypotension (progressing to shock), acute renal failure, thrombosis, delirious states, flaccid paralysis, apathy and confusion.

Treatment

The drug should be discontinued and appropriate corrective treatment applied: replacement of excessive fluid and electrolyte losses; serum electrolytes, carbon dioxide level and blood pressure should be determined frequently. Adequate drainage must be assured in patients with urinary bladder outlet obstruction (such as prostatic hypertrophy).

No specific antidote to furosemide is known. If ingestion has only just taken place, attempts may be made to limit further systemic absorption of the active ingredient by measures such as gastric lavage or those designed to reduce absorption (e.g. activated charcoal).

For management of a suspected drug overdose, contact your regional Poison Control Centre.

ACTION AND CLINICAL PHARMACOLOGY

Mechanism of Action

Animal experiments using stop-flow and micropuncture techniques have demonstrated that furosemide inhibits sodium reabsorption in the ascending limb of Henle's loop as well as in both proximal and distal tubules. The action of furosemide on the distal tubule is independent of any inhibitory effect on carbonic anhydrase or aldosterone.

Furosemide may promote diuresis in cases which have previously proved resistant to other diuretics.

Pharmacodynamics

A continuous infusion of furosemide is more effective than repetitive bolus injections. Moreover, above a certain bolus dose of the drug there is no significant increase in effect.

The effect of furosemide is reduced if there is lowered tubular secretion or intra-tubular albumin binding of the drug.

Pharmacokinetics

Absorption

In man, furosemide is rapidly absorbed from the gastro-intestinal tract. The diuretic effect of furosemide is apparent within one hour following oral administration and the peak effect occurs in the first or second hour. The duration of action is 4-6 hours but may continue up to 8 hours. Following intravenous administration of the drug, the diuresis occurs within 30 minutes and the duration of action is about 2 hours.

Metabolism

A small fraction is metabolized by cleavage of the side chain.

Excretion

Urinary excretion is accomplished both by glomerular filtration and proximal tubular secretion, together this accounts for roughly only 2/3 of the ingested dose, the remainder being excreted in the feces.

The following table summarizes the elimination kinetics of furosemide.

Table 1 - Summary of furosemide's elimination kinetics.

Subjects	Route of Administration	Dose (mg)	Rate of Administration	Biliary Excretion	Max. Serum Concentration	t _{1/2} (hr)
Normal	Oral	40	—	10-15%	< 1 µg /mL	4.0
Normal	I.V.	40	Bolus	10-15%	2.5 µg/mL	4.5
Renal insufficiency	I.V.	1000	25 mg/min.	60%	53 µg /mL	13.5
Renal insufficiency	I.V.	1000	4 mg/min.	—	29 µg /mL	—

Special Populations and Conditions

Pediatrics: Depending on the maturity of the kidney, the elimination of furosemide may be slowed down. The metabolism of the drug is also reduced if the infant's glucuronisation capacity is impaired.

The terminal half-life is below 12 hours in infants with a post-conceptual age of more than 33 weeks.

In infants of 2 months and older, the terminal clearance is the same as in adults.

Geriatrics: The elimination of furosemide is slowed down due to reduced renal function in the elderly.

Gender: Data unavailable.

Race: Data unavailable.

Hepatic Insufficiency: In liver failure, the half-life of furosemide is increased by 30% to 90% mainly due to a larger volume of distribution. Additionally, in this patient group there is a wide variation in all pharmacokinetic parameters.

Renal Insufficiency: In renal failure, the elimination furosemide is slowed down and the half-life prolonged; the terminal half-life may be up to 24 hours in patients with severe renal failure.

In nephrotic syndrome the reduced plasma protein concentration leads to a higher concentration of unbound (free) furosemide. On the other hand, efficacy of furosemide is reduced in these patients due to binding to intratubular albumin and lowered tubular secretion.

Furosemide is poorly dialyzable in patients undergoing haemodialysis, peritoneal dialysis and CAPD.

Genetic Polymorphism: Data unavailable.

STORAGE AND STABILITY

Temperature

Tablets: Store between 15° and 30°C. Protect from light.

DOSAGE FORMS, COMPOSITION AND PACKAGING

MINT-FUORSEMIDE tablets, 20 mg

White to off white, uncoated, round shaped debossed with 'F20' on one side and leaf logo on other side. Available in bottles of 30s and 1000s tablets.

Non-medicinal ingredients: corn starch, lactose monohydrate, magnesium stearate, pregelatinized starch and sodium starch glycolate.

MINT-FUORSEMIDE tablets, 40 mg

Yellow colored, uncoated, round shaped tablets, debossed with 'F' and '40' on either side of break line on one side & leaf logo on other side. Available in bottles of 30s and 1000s tablets.

Non-medicinal ingredients: Color D&C Yellow No. 10, corn starch, FD&C Yellow No. 6 Aluminum Lake, lactose monohydrate, magnesium stearate, pregelatinized starch and sodium starch glycolate.

MINT-FUORSEMIDE tablets, 80 mg

Yellow colored, uncoated, caplet shaped tablets, debossed with 'F' and '80' on either side of break line on one side & leaf logo on other side. Available in bottles of 30s and 1000s tablets.


Non-medicinal ingredients: Color D&C Yellow No. 10, corn starch, FD&C Yellow No. 6 Aluminum Lake, lactose monohydrate, magnesium stearate, pregelatinized starch and sodium starch glycolate.

PART II: SCIENTIFIC INFORMATION

PHARMACEUTICAL INFORMATION

Drug Substance

Proper name:	furosemide
Chemical name:	4-chloro-N-furfuryl-5-sulfamoyl-anthranilic acid
Molecular formula:	$C_{12}H_{11}ClN_2O_5S$
Molecular mass:	330.8 g/mol
Structural formula:	



Physicochemical properties: White to slightly yellow, crystalline powder. Practically insoluble in water; freely soluble in acetone, in dimethylformamide, and in solutions of alkali hydroxides; soluble in methanol; sparingly soluble in alcohol; slightly soluble in ether; very slightly soluble in chloroform, melting at about 210°C (with decomposition).

CLINICAL TRIALS

Comparative Bioavailability Study

A blinded, randomized, two-treatment, three-sequence, three-period, reference replicate, single oral dose, bioequivalence study of MINT-FUROSEMIDE (furosemide) 40 mg tablets (Mint Pharmaceuticals Inc.) and LASIX[®] (furosemide tablets USP) 40 mg tablets (Sanofi-Aventis Canada Inc.) in 43 healthy male subjects (between the ages of 20 and 43 years old) was conducted under fasting conditions. The results are tabulated below.

SUMMARY TABLE OF THE COMPARATIVE BIOAVAILABILITY DATA

Furosemide (1 x 40 mg) From measured data Geometric Mean Arithmetic Mean (CV %)				
Parameter	Test*	Reference†	% Ratio of Geometric Means	90% Confidence Interval
AUC _{0-t} (ng.hr/mL)	4270.68 (1124.56) 26.33	4085.35 (1190.06) 29.13	104.35	(99.80 – 109.10)
AUC _{0-∞} (ng.hr/mL)	4368.70 (1126.90) 25.79	4177.07 (1201.43) 28.76	104.49	(100.06 – 109.12)
C _{max} (ng/mL)	1985.46 (662.58) 33.37	1887.17 (707.55) 37.49	104.00	(95.29 – 113.52)
T _{max} [§] (h)	1.25 (0.50 – 4.50)	1.50 (0.33 – 4.25)		
T _{1/2} [€] (h)	2.37 (34.28)	2.21 (23.82)		

* MINT-FUROSEMIDE (furosemide) 40 mg tablet (Mint Pharmaceuticals Inc.)

† LASIX[®] (furosemide tablets USP) 40 mg tablets (Sanofi-Aventis Canada Inc.) were purchased in Canada.

§ Expressed as median (range).

€ Expressed as arithmetic mean (CV%) only.

DETAILED PHARMACOLOGY

Furosemide has no significant pharmacological effects other than on the renal function.

Renal Pharmacology

In dogs, furosemide demonstrated diuretic properties. Diuresis and sodium excretion were induced by doses of 0.125 mg/kg administered intravenously or 0.5 mg administered orally.

Maximum water and sodium excretion is obtained by oral and intravenous doses of 12.5 and 25 mg/kg respectively. Increased potassium excretion can only be demonstrated with doses exceeding 1 mg/kg. The onset of action is rapid after intravenous and oral administration and the duration of activity is approximately 2 and 4 hours respectively.

Furosemide produces an immediate diuresis after intravenous administration and is effective unilaterally after injection into a renal artery. Its action, therefore, is directly on the kidney. The diuretic response is prompt and relatively brief. At the peak of diuretic response 30-40% of filtered sodium load may be excreted, along with some potassium and with chloride as the major

anion. Furosemide augments the potassium output as a result of increased distal potassium secretion. Its diuretic action is independent of changes in acid-base balance. Under conditions of acidosis or alkalosis the diuretic produces chloruresis without augmentation of bicarbonate excretion. It does not inhibit carbonic anhydrase.

On the basis of changes in free-water production furosemide inhibits sodium reabsorption in the ascending limb of Helves loop. However, proximal sites of action are also involved, as determined by micropuncture. Partial distal inhibition of sodium reabsorption is also possible. It also decreases the urinary excretion of uric acid and prolonged administration may lead to hyperuricemia. Since urate is transported in the proximal tubule, the effect of the drug on uric acid excretion further suggests a proximal tubule site of action.

Administration of furosemide may induce extracellular metabolic alkalosis, primarily by virtue of the disproportionate loss of chloride, but also, in part, as a result of the variable depletion of potassium.

TOXICOLOGY

The acute toxicity of furosemide has been determined in four animal species:

Table 2 - **ACUTE TOXICITY (LD₅₀) OF FUROSEMIDE**
(Approximate doses in mg/kg)

SPECIES	ORAL	INTRAVENOUS
Mice	1000	300
Adult Rats	4600	700
Newborn Rats	400	-
Rabbits	700	400
Dogs	2000	over 400

The acute toxicity was characterized by signs of vasomotor collapse, sometimes accompanied by slight convulsions. Surviving animals often became dehydrated and depleted of electrolytes. In the newborn rats, intragastric injection of the drug caused hyperactivity and anorexia.

Chronic toxicity studies with furosemide were done in rats, dogs and monkeys.

1. **Rats:** A one-year study was performed on one hundred albino rats at dosages of 0, 50, 100, 200 and 400 mg/kg/day orally. Seventy-six rats survived for one year. Ten rats from the two highest dose groups died within the first 10 days of therapy. Histological examination of those animals dying early revealed striking basophilic degeneration of the myocardial fibres with infiltration and necrotic foci consistent with severe electrolyte imbalance.

In the kidney, the most consistent pathological changes seen were degenerative changes in the tubular epithelium manifested by swollen cells with increased density of the cytoplasm. Occasionally, focal necrosis of the epithelium and decreased cell size were

evident, plus accumulation of some calcified material. These changes were considered consistent with the nephropathy of potassium deficiency.

2. **Dogs:** In a six-month study, eighteen out of twenty beagle dogs survived oral daily doses of 0, 10, 30, 100 and 350 mg/kg. The most consistent pathological findings were renal lesions consisting of calcifications and scarring of the renal parenchyma at all doses above 10 mg/kg. The renal capsule above these lesions sometimes showed strikingly enlarged lymph vessels with thickened walls.
3. **Rhesus Monkeys:** In a 12-month study, daily oral doses of furosemide of 27 mg/kg and 60 mg/kg brought about pathological findings that consisted of dilated convoluted tubules with casts in 3 out of 20 animals given 27 mg/kg and in 6 out of 9 animals given 60 mg/kg. These lesions were considered drug related.

Reproductive and teratological studies

Reproductive and teratological studies have been performed in mice, rats, rabbits, cats, dogs and monkeys. With the exception of mice and rabbits, no abnormalities attributed to furosemide were detected. Furosemide caused unexplained maternal deaths and abortions in the rabbit at a daily dose of 50 mg/kg (approximately three times the maximum recommended human daily dose of 1000 mg orally) when administered between days 12 to 17 of gestation. In another study in rabbits, a dose of 25 mg/kg caused maternal deaths and abortions. In a third study, none of the pregnant rabbits survived a dose of 100 mg/kg. Data from the above studies indicate foetal lethality which can precede maternal deaths.

The results of a mouse study and one of the three rabbit studies also showed an increased incidence of distention of the renal pelvis and, in some cases, of the ureters in foetuses derived from treated dams as compared to the incidence of foetuses from the control group.

REFERENCES

1. CHAN, G.Y.F.: Competitive binding of bilirubin to albumin. M.Sc. Thesis, Department of Experimental Medicine, McGill University, 1971.
2. BRENNER, B.M., et al.: An inhibitory effect of furosemide on sodium reabsorption by the proximal tubule of the rat nephron. *J. Clin. Invest.*, 48: 290-300, 1969.
3. FRASER, A.G., et al.: The effects of furosemide on the osmolality of the urine and the composition of renal tissue. *J. Pharmacol. Exp. Ther.*, 158: 475-486, 1967.
4. SUKI, W., et al.: The site of action of furosemide and other sulfonamide diuretics in the dog. *J. Clin. Invest.*, 44: 1458-1469, 1965.
5. MORRIN, P.A.F.: The effect of furosemide, a new diuretic agent, on renal concentrating and diluting mechanisms. *Can. J. Physiol. Pharmacol.*, 44: 129-137, 1966.
6. STEIN, J.H., et al.: Differences in the acute effects of furosemide and ethacrynic acid in man. *J. Lab. Clin. Med.*, 17: 654-665, 1968.
7. MUSCHAWECK, R. & HADJU, P.: Die salidiuretische Wirksamkeit der Chlor-N-(2-furylmethyl)-5-sulfamyl-anthranilisaure. *Arzn.-Forsch.*, 14: 44-47, 1964.
8. BIRTCH, A.G., et al.: Redistribution of renal blood flow produced by furosemide and ethacrynic acid. *Circulation Res.*, 21: 869-878, 1967.
9. HOOK, J.B., et al.: Effects of several saluretic diuretic agents on renal hemodynamics. *J. Pharmacol. Exp. Ther.*, 154: 667-673, 1966.
10. QUICK, C.A. & HOPPE, W.: Permanent deafness associated with furosemide administration. *Ann. Otol.*, 34: 94-101, 1975.
11. CUTLER, R.E., et al.: Pharmacokinetics of furosemide in normal subjects and functionally anephric patients. *Clin. Pharmacol. Ther.*, 15: 588-596, 1974.
12. HUANG, C.M., et al.: Pharmacokinetics of furosemide in advanced renal failure. *Clin. Pharmacol. Ther.*, 16: 659-666, 1974.
13. PRANDOTTA, J. & PRUITT, A.W.: Furosemide binding to human albumin and plasma of nephrotic children. *Clin. Pharmacol. Ther.*, 17: 159-166, 1975.
14. KELLY, M.R., et al.: Pharmacokinetics of orally administered furosemide. *Clin. Pharmacol. Ther.*, 15: 178-186, 1974.

15. RUPP, W.: The Pharmacokinetics of furosemide in health and renal disease. In "Die Anwendung hoher Furosemiddosen in der Klinik", pp. 24-30, Medicus Verlag GmbH, Berlin, 1973.
16. LASIX[®] (furosemide tablets USP) Product Monograph. Sanofi-Aventis Canada Inc. Date of Revision: December 10, 2013(Control #168106).

PART III: CONSUMER INFORMATION

Pr MINT-FUROSEMIDE
furosemide
20 mg, 40 mg and 80 mg Tablets
USP

This leaflet is part III of a three-part "Product Monograph" published for MINT-FUROSEMIDE in Canada and is designed specifically for Consumers. This leaflet is a summary and will not tell you everything about MINT-FUROSEMIDE. Contact your doctor or pharmacist if you have any questions about the drug.

ABOUT THIS MEDICATION

What the medication is used for:

MINT-FUROSEMIDE has been prescribed to you by your health provider to treat your edema (water retention) or hypertension (high blood pressure).

What it does:

MINT-FUROSEMIDE belongs to a group of medicines known as diuretic drugs which improve the elimination of water and salts (electrolytes) in the urine.

When it should not be used:

Do not use MINT-FUROSEMIDE if you are allergic to it or to any of the components of its formulation (for list of components see the section on "What the nonmedicinal ingredients are"), or to any sulfonamide-derived drugs. Ask your physician or pharmacist if you are not sure what sulfonamide-derived drugs are.

Do not use MINT-FUROSEMIDE if:

- You are suffering kidney failure, hepatic (liver) coma or precoma disease
- You have electrolyte depletion (loss of blood salts e.g. dehydration, hot weather, excessive sweating...) or severe hyponatremia (low blood sodium), hypokalemia (low blood potassium), hypovolemia (low blood volume), hypotension (low blood pressure) or dehydration until your electrolytes and fluid balance are restored.
- Your newborn infant has jaundice (yellowing of the skin and/or eyes) or infants suffering from certain diseases (e.g. Rh incompatibility, familial non-hemolytic jaundice (yellowing of the skin and/or eyes without evidence of liver damage))
- Do not breastfeed if you intend to use MINT-FUROSEMIDE.

What the medicinal ingredient is:

Furosemide

What the nonmedicinal ingredients are:

20 mg tablets: corn starch, lactose monohydrate, magnesium stearate, pregelatinized starch and sodium starch glycolate.

40 mg tablets: corn starch, FD&C Yellow No. 6 Aluminum Lake, lactose monohydrate, magnesium stearate, pregelatinized starch and sodium starch glycolate.

80 mg tablets: Color D&C Yellow No. 10, corn starch, FD&C Yellow No. 6 Aluminum Lake, lactose monohydrate, magnesium stearate, pregelatinized starch and sodium starch glycolate.

What dosage forms it comes in:

Tablets of 20 mg, 40 mg and 80 mg.

WARNINGS AND PRECAUTIONS

MINT-FUROSEMIDE IS A VERY STRONG WATER PILL WHICH IF GIVEN IN EXCESSIVE AMOUNTS CAN LEAD TO A PROFOUND WATER AND ELECTROLYTE LOSS FROM THE BODY. THEREFORE, CAREFUL MEDICAL SUPERVISION IS REQUIRED. THE DOSE AND DOSE SCHEDULE HAVE TO BE ADJUSTED TO THE INDIVIDUAL PATIENT'S NEEDS.

BEFORE you use MINT-FUROSEMIDE talk to your health provider if:

- You have decreased blood pressure
- You have liver disease or disorder
- You have kidney disease or disorder
- It is suspected you might be diabetic (high blood sugar)
- You have decreased ability to pass urine
- You had an organ transplant
- You have gout
- You have been told by the doctor that you suffer from a narrowing of the arteries that supply your heart or brain
- You have recently suffered from excess vomiting or diarrhea
- You intend to have a surgery and general anesthesia (even at the dentist's office), as there may be a sudden fall in blood pressure associated with general anesthesia
- You are breastfeeding. Furosemide is passed to the infant during breastfeeding. Do not breastfeed if you intend to take MINT-FUROSEMIDE
- You are pregnant, or think you might be pregnant

IMPORTANT: PLEASE READ

- You intend to change your eating habits
- You are less than 18 years old
- You are older than 61 years old

When administered to children, MINT-FUROSEMIDE therapy should be started in the hospital, in carefully selected patients, under close observation with frequent blood tests to measure electrolytes such as sodium, potassium, chloride, magnesium and calcium.

For elderly patients, (over 61 years old), the dose selection should be cautious, usually starting at the low end of dosage range, reflecting the greater frequency of decreased liver, kidney or heart function.

Studies in elderly patients with dementia have shown that taking furosemide with risperidone is associated with a higher rate of death.

The administration of MINT-FUROSEMIDE to diabetic patients may result in possible decrease of diabetic control. Dosage adjustments of the antidiabetic agent may be needed.

There have been cases of ringing in the ears, reversible and non-reversible deafness especially in children. This is most true when the patient has severe kidney disease or is taking drugs that are known to sometimes damage the ears while they are taking furosemide. Your doctor will decide if MINT-FUROSEMIDE is the right medication for you/your child based on your particular condition.

MINT-FUROSEMIDE should not be used in pregnant women or in women of childbearing potential unless in the opinion of the attending physician the benefits to the patient outweigh the possible risk to the foetus. Treatment during pregnancy requires monitoring of fetal growth by your doctor.

If you are suffering from hyperuricemia (high uric acid levels in your blood), taking MINT-FUROSEMIDE can sometimes make a gout attack more likely.

Almost all patients can drive or operate machinery while taking MINT-FUROSEMIDE, but you should not perform these tasks, which may require attention, until you know how you tolerate your medicine.

INTERACTIONS WITH THIS MEDICATION

Before using MINT-FUROSEMIDE, tell your health provider about medication you are currently taking. This way appropriate adjustment and decision can be taken for your treatment with MINT-FUROSEMIDE.

Below are drugs or drug classes that may interact

with MINT-FUROSEMIDE These include:

- Drugs to reduce blood pressure (eg. ACE inhibitors, angiotensin II receptor antagonist)
- Diuretics (waterpills), including ethacrynic acid
- Pressor amines such as epinephrine (a medication used to treat life-threatening allergic reactions)
- Medication to treat diabetes, including insulin. The administration of MINT-FUROSEMIDE to diabetic patients may result in possible decrease of diabetic control. Dosage adjustments of the antidiabetic agent may be needed.
- Theophylline, a medication used to treat asthma, chronic bronchitis, and other lung diseases
- Cisplatin (anti-cancer drug)
- Probenecid (medicine used to treat gout)
- Antibiotics (e.g cephalosporins, aminoglycosides)
- Certain pain and anti-inflammatory drugs (e.g non-steroidal anti-inflammatory drugs [NSAIDs], acetyl-salicylic acid, indomethacin)
- Drugs used in the treatment of rheumatoid arthritis (methotrexate, cyclosporin)
- Drugs used to treat epilepsy (e.g. phenytoin, carbamazepine, phenobarbital)
- Risperdal, a drug used to treat dementia
- Lithium (medicine used to treat bipolar depression)
- Sucralfate (antacid drug)
- Sedatives such as phenobarbital or chloral hydrate
- Stimulant laxatives and drugs which may induce low potassium levels (hypokalemia) such as glucocorticoids, and medicine derived from licorice (eg. carbenoxolone)
- Drugs known to be harmful to the ear (ototoxic) as for instance aminoglycosides antibiotics, ethacrynic acid (a “water pill”) and cisplatin (a drug used to treat some types of cancer)
- Drugs known to be harmful to the kidney
- Substances used during certain radiological investigations (radiocontrast agents).
- Digitalis (digoxin)
- Certain steroids.

PROPER USE OF THIS MEDICATION

During long-term therapy a high-potassium diet may be recommended. You should not be on a strict salt restricted diet. Potassium supplements may be required. Your doctor will monitor your blood tests for blood sugar, potassium and other electrolytes and to monitor liver and kidney function. This is especially important if you have other medical conditions such as diabetes, take other medications or the patient is an infant or child.

IMPORTANT: PLEASE READ

Usual dose:

Adults (oral) for edema and high blood pressure:

It is important that you take MINT-FUROSEMIDE as prescribed by your doctor.

Usually your doctor will prescribe MINT-FUROSEMIDE tablets at a dose of 20 to 80 mg per day, which you could take as single or 2-3 divided doses, based on the type of administration your physician considers to be the most appropriate for your condition.

Maximum daily dose: 200 mg.

Swallow the tablets whole with a glass of water.

You should always respect the prescribed interval between the doses. Never change the dose of MINT-FUROSEMIDE you are taking unless your doctor tells you to.

This drug is specifically prescribed for you or a child in your care. Do not give it to others, even if they have the same symptoms, and you yourself must not use it for any condition than the one for which it was prescribed.

Overdose:

In case of drug overdose, contact a health care practitioner, hospital emergency department or regional Poison Control Centre immediately, even if there are no symptoms.

SIDE EFFECTS AND WHAT TO DO ABOUT THEM

Along with its beneficial effects, MINT-FUROSEMIDE like all other drugs may sometimes cause undesirable effects. These may include: blurring of vision, constipation, diarrhea,

dizziness, dry mouth, fatigue, tachycardia, arrhythmia (heart rhythm disturbance), feeling of pressure in the head, increase in the amount and frequency of your urine, leg cramps, mental confusion, nausea, sweating, thirst, vomiting, hepatic encephalopathy (altered mental state due to liver disease). Talk to your doctor or pharmacist if you experience any of the above.

Stop taking MINT-FUROSEMIDE and contact your doctor immediately if you experience an allergic reaction or any severe side effect.

SERIOUS SIDE EFFECTS, HOW OFTEN THEY HAPPEN AND WHAT TO DO ABOUT THEM			
Symptom / effect	Talk with your doctor or pharmacist immediately		Stop taking drug and seek immediate emergency
	Only if severe	In all cases	
Hearing problems		✓	
Fever, sore throat, fatigue, lesions in the mouth or on the lips			✓
Skin rash and/or blistering			✓
Hives and/or itching			✓
Abdominal pain		✓	
Difficulty to urinate			✓
Low blood pressure (hypotension): dizziness when rising to a standing position, impaired concentration and lightheadedness		✓	

IMPORTANT: PLEASE READ

SERIOUS SIDE EFFECTS, HOW OFTEN THEY HAPPEN AND WHAT TO DO ABOUT THEM			
Symptom / effect	Talk with your doctor or pharmacist immediately		Stop taking drug and seek immediate emergency medical attention
	Only if severe	In all cases	
Yellow coloration of the skin (jaundice)			✓
Dehydration and/or abnormal blood tests: dryness of the mouth, thirst, weakness, dizziness, lethargy, drowsiness, restlessness, muscle pain or cramps, muscular fatigue, hypotension, racing or irregular heartbeats, nausea and vomiting, sweating, increases in blood sugar levels, increased urination, mental confusion, headache			✓
Pseudo-Bartter syndrome: abnormal blood tests, fatigue, muscle weakness, diarrhea, dehydration, increased thirst, increased urination, low blood pressure, irregular heartbeats			✓
Blurred vision		✓	
Allergic reactions: eyes sensitive to light, tingling of fingers or toes, fever			✓
Blood clots: pain, swelling tenderness in your leg or arm, warm, red skin and a heavy feeling in the affected area			✓
Failure of the kidneys: weakness, trouble breathing, swelling, fast or irregular heartbeat, confusion, decrease or inability to urinate, loss of appetite, coma and death			✓

SERIOUS SIDE EFFECTS, HOW OFTEN THEY HAPPEN AND WHAT TO DO ABOUT THEM			
Symptom / effect	Talk with your doctor or pharmacist immediately		Stop taking drug and seek immediate emergency medical attention
	Only if severe	In all cases	
In premature babies: discoloured urine and /or blood in the urine/diaper, fever and chills, vomiting, excessive crying or other signs the baby is in pain			✓
In premature babies: poor weight gain		✓	

Although not all of the above side effects are common, if you experience one of these while you are in the hospital or at home, talk to your doctor or pharmacist immediately.

This is not a complete list of side effects. For any unexpected effects while taking MINT-FUROSEMIDE, contact your doctor or pharmacist

HOW TO STORE IT

Store your tablets and solution at room temperature (15°C– 30°C). Protect from light.

There is an expiration date on the label. Do not use the medicine after this date.

Return any leftover tablets/solution to the pharmacist, unless the doctor tells you to keep them at home.

As with all medicines, keep MINT-FUROSEMIDE out of reach and sight of children.

REPORTING SUSPECTED SIDE EFFECTS

You can report any suspected adverse reactions associated with the use of health products to the Canada Vigilance Program by one of the following 3 ways:

- Report online at:
www.healthcanada.gc.ca/medeffect
- Call toll-free at 1-866-234-2345
- Complete a Canada Vigilance Reporting Form and:
 - Fax toll-free to 1-866-678-6789, or
 - Mail to: Canada Vigilance Program
Health Canada
Postal Locator 1908C
Ottawa, ON K1A 0K9

Postage paid labels, Canada Vigilance Reporting Form and the adverse reaction reporting guidelines are available on the MedEffect™ Canada Web site at www.healthcanada.gc.ca/medeffect.

NOTE: Should you require information related to the management of side effects, contact your health professional. The Canada Vigilance Program does not provide medical advice.

MORE INFORMATION

This document plus the full product monograph, prepared for health professionals can be found by contacting the sponsor, Mint Pharmaceuticals Inc. at: 1-877-398-9696.

This leaflet was prepared by Mint Pharmaceuticals Inc.

Prepared on: July 21, 2017